Literature DB >> 1378801

Cystic fibrosis transmembrane conductance regulator and the etiology and pathogenesis of cystic fibrosis.

I McIntosh1, G R Cutting.   

Abstract

Cystic fibrosis (CF) is an inherited disorder causing pancreatic, pulmonary, and sinus disease in children and young adults. Abnormal viscosity of mucous secretions is a hallmark of the disease, and is believed to be the result of altered electrolyte transport across epithelial cell membranes. The monogenic etiology of this disease has been apparent for more than 40 years, but the defective gene has only recently been identified. This was made possible because of a revolution in genetic technology, called positional cloning, which can pinpoint disease genes without previous knowledge of the abnormal protein product. The protein encoded by the gene defective in CF has been termed the CF transmembrane conductance regulator (CFTR) because of its postulated role in electrolyte transport. Studies investigating the normal function of CFTR and how mutations affect that function, thereby causing CF, have required the combined skills of clinicians, geneticists, molecular biologists, and physiologists. From this collaborative effort a greater understanding of the pathogenesis of this disorder is now emerging. It may soon be possible to introduce novel therapies derived from this new knowledge that will be aimed directly at the basic defect. An ever-increasing number of genes of unknown function will be identified by continuing advances in molecular genetic technology and the advent of the genome sequencing project. The experience in cystic fibrosis research may prove to be a paradigm for investigation of the function of genes isolated by positional cloning methods.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378801     DOI: 10.1096/fasebj.6.10.1378801

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  11 in total

1.  CFTR mutations in Chilean cystic fibrosis patients.

Authors:  J Rios; O Orellana; M Aspillaga; I Avendano; I Largo; N Riveros
Journal:  Hum Genet       Date:  1994-09       Impact factor: 4.132

2.  The Epithelial Sodium Channel Is a Modifier of the Long-Term Nonprogressive Phenotype Associated with F508del CFTR Mutations.

Authors:  Pankaj B Agrawal; Ruobing Wang; Hongmei Lisa Li; Klaus Schmitz-Abe; Chantelle Simone-Roach; Jingxin Chen; Jiahai Shi; Tin Louie; Shaohu Sheng; Meghan C Towne; Christine F Brainson; Michael A Matthay; Carla F Kim; Michael Bamshad; Mary J Emond; Norma P Gerard; Thomas R Kleyman; Craig Gerard
Journal:  Am J Respir Cell Mol Biol       Date:  2017-12       Impact factor: 6.914

Review 3.  Spectrum of mutations in cystic fibrosis.

Authors:  G R Cutting
Journal:  J Bioenerg Biomembr       Date:  1993-02       Impact factor: 2.945

4.  The what, where, when and how of Wnt/β-catenin signaling in pancreas development.

Authors:  L Charles Murtaugh
Journal:  Organogenesis       Date:  2008-04       Impact factor: 2.500

Review 5.  What's new in cystic fibrosis? From treating symptoms to correction of the basic defect.

Authors:  Marijke Proesmans; François Vermeulen; Kris De Boeck
Journal:  Eur J Pediatr       Date:  2008-04-04       Impact factor: 3.183

6.  Neutrophil elastase enhances sputum solubilization in cystic fibrosis patients receiving DNase therapy.

Authors:  Venizelos Papayannopoulos; Doris Staab; Arturo Zychlinsky
Journal:  PLoS One       Date:  2011-12-09       Impact factor: 3.240

7.  Neutrophil-derived Oxidants and Proteinases as Immunomodulatory Mediators in Inflammation.

Authors:  V Witko-Sarsat; B Descamps-Latscha
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

8.  Gene mutation in microRNA target sites of CFTR gene: a novel pathogenetic mechanism in cystic fibrosis?

Authors:  Felice Amato; Manuela Seia; Sonia Giordano; Ausilia Elce; Federica Zarrilli; Giuseppe Castaldo; Rossella Tomaiuolo
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

Review 9.  Molecular mechanisms regulating NETosis in infection and disease.

Authors:  Nora Branzk; Venizelos Papayannopoulos
Journal:  Semin Immunopathol       Date:  2013-06-04       Impact factor: 9.623

10.  Exploitation of a very small peptide nucleic acid as a new inhibitor of miR-509-3p involved in the regulation of cystic fibrosis disease-gene expression.

Authors:  Felice Amato; Rossella Tomaiuolo; Fabrizia Nici; Nicola Borbone; Ausilia Elce; Bruno Catalanotti; Stefano D'Errico; Carmine Marco Morgillo; Giuseppe De Rosa; Laura Mayol; Gennaro Piccialli; Giorgia Oliviero; Giuseppe Castaldo
Journal:  Biomed Res Int       Date:  2014-04-15       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.